Please ensure Javascript is enabled for purposes of website accessibility

What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today

By Todd Campbell - Apr 13, 2016 at 4:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

New data from its trial of ARC-520 in hepatitis B ignited a rally.

Image source: Arrowhead Pharmaceuticals.

What: After reporting data from an early-stage study of its ARC-520 in hepatitis B patients, shares of Arrowhead Pharmaceuticals (ARWR 0.23%) shot 12.9% higher today.

So what: The clinical-stage researcher of drugs that target ribonucleic acid, a nucleic acid present in all living cells that acts as a DNA messenger, announced today that combining its ARC-520 with Bristol-Myers Squibb's (BMY -1.32%) commonly used Baraclude delivered significant efficacy in hepatitis B patients.

Specifically, the ARC-520 and entecavir combination therapy resulted in up to 5.5 log, or 99.99% reductions in serum HBV DNA. Additionally, patients with the tough-to-treat HBeAg negative mutation achieved reductions that put them below the limit of quantification. 

Those findings suggest that ARC-520 containing therapy could have the potential to offer a functional cure for the 350 million-plus people infected with hepatitis B worldwide.

Now what: Although the findings are encouraging, investors will need to rein in a bit of their enthusiasm. ARC-520 is currently in mid-stage trials, and more complete trial results should be available over the course of the coming year.

Assuming results from these trials are positive, then a larger, confirmatory phase 3 trial would likely be required prior to FDA approval. Because drugs often fall short in late-stage trials, we're still pretty far away from the finish line for this drug.

Having said that, the concept of significantly improving care in this large patient population is incredibly intriguing. Liver disease caused by hepatitis B can be life-threatening, and there's a significant need for new treatment alternatives that improve upon Baraclude and other existing standards of care.

Risk-tolerant investors might want to consider keeping an eye on this company, but they ought to remember that management is spending roughly $18.5 million per quarter, and the company has just $76.5 million in cash and equivalents on its books.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$76.00 (-1.32%) $-1.02
Arrowhead Pharmaceuticals, Inc. Stock Quote
Arrowhead Pharmaceuticals, Inc.
ARWR
$34.28 (0.23%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
328%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.